These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38988871)

  • 1. Addition of a Novel Qualitative Technique to Standard Quantitative Practices for Evaluation of Hazardous Drug Exposure in a Canadian Hospital Setting.
    Grewal R; Karas A; Goyal S
    Can J Hosp Pharm; 2024; 77(3):e3509. PubMed ID: 38988871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side-by-Side Comparison of Methods for Environmental Monitoring for Hazardous Drug Contamination.
    Hon CY
    Can J Hosp Pharm; 2023; 76(2):87-93. PubMed ID: 36998748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system.
    Brechtelsbauer E
    Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of chemical contamination by hazardous drugs with BD HD Check
    Valero García S; Centelles-Oria M; Palanques-Pastor T; Vila Clérigues N; López-Briz E; Poveda Andrés JL
    J Oncol Pharm Pract; 2022 Oct; 28(7):1583-1593. PubMed ID: 34565241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Current Hazardous Drug Exposure Control in Community Pharmacy.
    Papastergiou J; Smiley T
    J Pharm Technol; 2022 Jun; 38(3):155-158. PubMed ID: 35600277
    [No Abstract]   [Full Text] [Related]  

  • 6. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
    Gurusamy KS; Best LM; Tanguay C; Lennan E; Korva M; Bussières JF
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012860. PubMed ID: 29582940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental contamination with hazardous drugs in quebec hospitals.
    Bussières JF; Tanguay C; Touzin K; Langlois E; Lefebvre M
    Can J Hosp Pharm; 2012 Nov; 65(6):428-35. PubMed ID: 23288952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal evaluation of environmental contamination with hazardous drugs by surface wipe sampling.
    Sessink PJ; Tans B; Spriet I; Devolder D
    J Oncol Pharm Pract; 2024 Oct; 30(7):1181-1185. PubMed ID: 38115732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project.
    Eisenberg S
    Clin J Oncol Nurs; 2023 May; 27(3):267-273. PubMed ID: 37267492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.
    Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL
    Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a decontamination procedure in a pharmacy buffer room contaminated by 5 antineoplastic agents.
    Arpino P; Yeomelakis J; Oommen A
    Am J Health Syst Pharm; 2020 Dec; 77(24):2081-2088. PubMed ID: 33150407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers.
    Pinet E; Cirtiu CM; Caron N; Bussières JF; Tanguay C
    J Oncol Pharm Pract; 2024 Jan; 30(1):19-29. PubMed ID: 37021440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
    Valero-García S; González-Haba E; Gorgas-Torner MQ; Alonso-Herreros JM; Cercós Lletí AC; Poveda-Andrés JL; Calleja-Hernandez MÁ; Delgado-Sánchez O
    Farm Hosp; 2021 Mar; 45(2):96-107. PubMed ID: 33709894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial and Temporal Variability in Antineoplastic Drug Surface Contamination in Cancer Care Centers in Alberta and Minnesota.
    Jeronimo M; Arnold S; Astrakianakis G; Lyden G; Stewart Q; Petersen A; Chambers C; Malard Johnson D; Zimdars E; Kaup H; Davies HW
    Ann Work Expo Health; 2021 Aug; 65(7):760-774. PubMed ID: 33889938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assessment of exposed syringe inner walls as a route of exposure from hazardous drugs.
    Barta BT; Armistead LT; Eckel SF
    J Oncol Pharm Pract; 2024 Feb; ():10781552241231511. PubMed ID: 38378187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.